LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutton, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust and chair of the Steering Committee for the CARPO trial, will deliver his plenary presentation from the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, entitled "A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with AP and Accompanying SIRS - CARPO."
Conference Call and Webcast Details
Stockholders and other interested parties may access the call by following the instructions below. A live webcast of the event can also be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. The archived webcast will be available following the completion of the event.
Participant Webcast Link: https://app.webinar.net/4EanW4A2PXk
Click on the webcast link and complete the online registration form.
Upon registering, you will be connected to the online webcast.
Participant Dial-in Numbers: 1-646-357-8785 (US) and 1-800-836-8184 (international)
If prompted by the operator, ask to join the CalciMedica Phase 2b CARPO Full Data Set & Win Ratio call.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 600-1902
| Last Trade: | US$2.76 |
| Daily Change: | -0.01 -0.36 |
| Daily Volume: | 54,373 |
| Market Cap: | US$37.200M |
November 20, 2024 November 13, 2024 October 30, 2024 October 16, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
